Omalizumab: tested on its own
130 studies: no other medicine in its arm. Page 1 of 2. Open to participants first (7), then studies with results posted, then the rest; newest registration first within each.
- Oral Food Challenge After One to Two Doses of Omalizumab Treatment for Food AllergyRecruitingNCT07845552Phase 4How we knowReport a problem
- Clinical Trial of Omalizumab for Allergen Sensitized and Exposed Individuals With COPDRecruitingNCT07059091Phase 2How we knowReport a problem
- Omalizumab for the Treatment of Food Allergy in Patients With Elevated Total IgE LevelsRecruitingNCT06934200Phase 2How we knowReport a problem
- Effect of Omalizumab in the Skin of Food Allergy PatientsRecruitingNCT06618963Phase 4How we knowReport a problem
- Biologics and Sublingual ImmunotherapyNot yet recruitingNCT06027073Phase 4How we knowReport a problem
- Extending Omalizumab Treatment Intervals in Patients With Chronic Spontaneous UrticariaRecruitingNCT05916937Phase 4How we knowReport a problem
- Omalizumab Before Onset of ExacerbationsRecruitingNCT05332067Phase 2How we knowReport a problem
- To Compare Efficacy and Safety of CT-P39 and EU-approved Xolair in Patients With Chronic Spontaneous UrticariaCompletedNCT04426890Phase 3Results postedHow we knowReport a problem
- A Study to Assess the Impact of Omalizumab on Exercise Capacity, Physical Activity, and Sleep Quality in Participants With Moderate to Severe Allergic AsthmaTerminatedNCT04195958Phase 4Results postedHow we knowReport a problem
- To Compare the PK and Safety of Omalizumab (CT-P39, EU-approved Xolair, and US-licensed Xolair) in Healthy SubjectsCompletedNCT04018313Phase 1Results postedHow we knowReport a problem
- An Extension Study of Omalizumab in Participants With Chronic Rhinosinusitis With Nasal PolypsCompletedNCT03478930Phase 3Results postedHow we knowReport a problem
- Study of Efficacy and Safety of Omalizumab in Severe Japanese Cedar Pollinosis Adult and Adolescent PatientsCompletedNCT03369704Phase 3Results postedHow we knowReport a problem
- Study of Efficacy and Safety of Xolair® (Omalizumab) in Chinese Patients With Chronic Spontaneous UrticariaCompletedNCT03328897Phase 3Results postedHow we knowReport a problem
- A Clinical Trial of Omalizumab in Participants With Chronic Rhinosinusitis With Nasal PolypsCompletedNCT03280550Phase 3Results postedHow we knowReport a problem
- A Clinical Trial of Omalizumab in Participants With Chronic Rhinosinusitus With Nasal PolypsCompletedNCT03280537Phase 3Results postedHow we knowReport a problem
- Role of Immunoglobulin E (IgE) Bearing Cells in Chronic Idiopathic Urticaria (CIU)CompletedNCT03111628Phase 4Results postedHow we knowReport a problem
- Treatment of Idiopathic Angioedema With Xolair as Add-on TherapyCompletedNCT02966314Phase 4Results postedHow we knowReport a problem
- Sputum-derived Cellular Targets After Xolair (Omalizumab)TerminatedNCT02658877Phase 4Results postedHow we knowReport a problem
- Study Using Xolair in Rush Multi Oral Immunotherapy in Multi Food Allergic PatientsCompletedNCT02643862Phase 1/2Results postedHow we knowReport a problem
- Omalizumab in Chronic Spontaneous Urticaria Patients Non Responding to Initial Standard antihistaminE TreatmentCompletedNCT02550106Phase 4Results postedHow we knowReport a problem
- A Study of the Efficacy and Safety of Omalizumab Through 48 Weeks in Participants With Chronic Idiopathic UrticariaCompletedNCT02392624Phase 4Results postedHow we knowReport a problem
- Study of Efficacy and Safety of Omalizumab in Refractory Chronic Spontaneous Urticaria PatientsCompletedNCT02329223Phase 3Results postedHow we knowReport a problem
- Omalizumab in Severe and Refractory Solar UrticariaCompletedNCT02262130Phase 2Results postedHow we knowReport a problem
- Urticaria Facticia Treatment With Omalizumab (UFO)CompletedNCT02169115Phase 2Results postedHow we knowReport a problem
- OPTIMA: Efficacy of Optimized Re-treatment and Step-up Therapy With Omalizumab in Chronic Spontaneous Urticaria (CSU) PatientsCompletedNCT02161562Phase 3Results postedHow we knowReport a problem
- Predicting the Clinical Response to Omalizumab With Anti-Immunoglobulin E (IgE) Ab Response or Syk Expression in BasophilsCompletedNCT02023151Phase 4Results postedHow we knowReport a problem
- A Study in Participants With Asthma Initiating Treatment With Omalizumab (Xolair)CompletedNCT01922037Phase 4Results postedHow we knowReport a problem
- Peanut Reactivity Reduced by Oral Tolerance in an Anti-IgE Clinical TrialCompletedNCT01781637Phase 1/2Results postedHow we knowReport a problem
- Impact of Omalizumab on Quality of Life Measures and Angioedema Occurrence in Patients With CSU Refractory to TherapyCompletedNCT01723072Phase 3Results postedHow we knowReport a problem
- Effect of Omalizumab (Xolair) on Basophils in Patients With Chronic Idiopathic UrticariaCompletedNCT01701583Phase 4Results postedHow we knowReport a problem
- Mode of Action Study of Omalizumab in Patients With Chronic Idiopathic Urticaria (CIU) Who Fail to Respond to Antihistamine TreatmentCompletedNCT01599637Phase 2Results postedHow we knowReport a problem
- Cold Urticaria Treatment With XolairCompletedNCT01580592Phase 2Results postedHow we knowReport a problem
- A Study to Evaluate the Efficacy, Response Duration and Safety of Xolair (Omalizumab) in Patients With Chronic Idiopathic Urticaria (CIU)/Chronic Spontaneous Urticaria (CSU) Who Remain Symptomatic Despite Antihistamine Treatment (H1)CompletedNCT01292473Phase 3Results postedHow we knowReport a problem
- Xolair Enhances Oral Desensitization in Peanut Allergic PatientsCompletedNCT01290913Phase 1/2Results postedHow we knowReport a problem
- A Study of the Efficacy and Safety of Omalizumab (Xolair) in Patients With Chronic Idiopathic Urticaria (CIU)/Chronic Spontaneous Urticaria (CSU) Who Remain Symptomatic Despite Antihistamine (H1) TreatmentCompletedNCT01287117Phase 3Results postedHow we knowReport a problem
- Omalizumab in Patients With Moderate to Severe Persistent Allergic Asthma Not Adequately Controlled Despite GINA (2009) Step 4 TherapyCompletedNCT01202903Phase 3Results postedHow we knowReport a problem
- Subcutaneous Omalizumab for Treatment of Chronic Rhinosinusitis With Nasal PolyposisCompletedNCT01066104Phase 2Results postedHow we knowReport a problem
- Effect of Omalizumab in Patients With Severe Persistent Non-atopic Uncontrolled AsthmaCompletedNCT01007149Phase 3Results postedHow we knowReport a problem
- The Effects of Omalizumab (Anti-IgE) on the Late-phase Response to Nasal Allergen ChallengeCompletedNCT01003301Phase 2Results postedHow we knowReport a problem
- Omalizumab in the Treatment of Peanut AllergyCompletedNCT00949078Phase 2Results postedHow we knowReport a problem
- Evaluate the Effect of Omalizumab on Markers of Asthma Impairment in Patients With Persistent Allergic AsthmaCompletedNCT00870584Phase 4Results postedHow we knowReport a problem
- Role of RhuMab-E25 in Reducing Exhaled Nitric Oxide (NO) in Allergic AsthmaCompletedNCT00829179Phase 3Results postedHow we knowReport a problem
- A Study of Efficacy of New Doses of Xolair to Protect From Allergen Challenge in Groups of Asthma Patients Defined by IgE LevelsCompletedNCT00624832Phase 4Results postedHow we knowReport a problem
- The Effect of Omalizumab on Responses to Cat Allergen ChallengeCompletedNCT00604786Not applicableResults postedHow we knowReport a problem
- Therapeutic Utility of Xolair in Patients Undergoing Aspirin DesensitizationCompletedNCT00555971Phase 4Results postedHow we knowReport a problem
- Open Label Study to Assess Safety and Immunogenicity of Omalizumab Liquid Formulation.CompletedNCT00500539Phase 3Results postedHow we knowReport a problem
- A Study of Omalizumab in Preventing Bronchoconstriction Following Environmental Cat Dander Exposure in Patients With Cat Dander-induced AsthmaCompletedNCT00495612Phase 4Results postedHow we knowReport a problem
- Efficacy and Safety of Omalizumab in Bullous PemphigoidCompletedNCT00472030Phase 4Results postedHow we knowReport a problem
- Effect of Omalizumab on Expression of IgE Receptors in Adults With Severe, Inadequately Controlled Allergic AsthmaCompletedNCT00454051Phase 4Results postedHow we knowReport a problem
- A Study of Omalizumab in the Prevention of Allergen Induced Airway Obstruction in Adults With Mild Allergic AsthmaCompletedNCT00434434Phase 2Results postedHow we knowReport a problem
- A Study of Xolair in Peanut-Allergic Subjects Previously Enrolled in Study Q2788gCompletedNCT00382148Phase 2Results postedHow we knowReport a problem
- Inner-City Anti-IgE Therapy for AsthmaCompletedNCT00377572Phase 4Results postedHow we knowReport a problem
- Immunologic Basis of Anti-IgE Therapy (Study II: On Patients With Asthma)CompletedNCT00367016Phase 4Results postedHow we knowReport a problem
- A Description of Inflammatory Cell Types In Moderate to Severe Pediatric Asthma: Eosinophilic and Non Eosinophilic Sputum Markers While on Anti-IgE TherapyCompletedNCT00283504Phase 4Results postedHow we knowReport a problem
- Omalizumab in Adult and Adolescent Patients With Severe Persistent Allergic AsthmaCompletedNCT00264849Phase 4Results postedHow we knowReport a problem
- Immune Dysfunction in Allergic AsthmaCompletedNCT00189228Not applicableResults postedHow we knowReport a problem
- Effect of Anti-IgE in Non-Allergic AsthmaTerminatedNCT00162773Phase 2Results postedHow we knowReport a problem
- A Pilot Study of the Treatment of Eosinophilic Esophagitis With OmalizumabCompletedNCT00123630Phase 2Results postedHow we knowReport a problem
- A Prospective, Randomized, Double-Blind Study of the Efficacy of Omalizumab (Xolair) in Atopic Asthmatics With Good Lung Capacity Who Remain Difficult to Treat (EXACT)CompletedNCT00096954Phase 4Results postedHow we knowReport a problem
- The Effect of Omalizumab on Allergic Rhinitis Symptoms: a Comparative StudyCompletedNCT06806826Phase 4How we knowReport a problem
- FeNO as a Marker of Allergic Reactions to OFC and Response of OMA Treatment in Multiple FACompletedNCT06437171Phase 4How we knowReport a problem
- PK, PD, Safety & Immunogenicity of ADL-018 Lyo in Healthy Adult SubjectsCompletedNCT05564611Phase 1How we knowReport a problem
- Omalizumab Efficacy in Patients With Refractory Nasal PolypsStatus unknownNCT05405478Phase 4How we knowReport a problem
- Study to Evaluate the Therapeutic Equivalence of SYN008 Versus Xolair® in the Treatment of Patients With Refractory Chronic Spontaneous UrticariaStatus unknownNCT04944602Phase 3How we knowReport a problem
- The Study of Omalizumab (CMAB007 and Xolair) in Healthy Subjects to Compare the PK, PD and SafetyCompletedNCT04778137Phase 1How we knowReport a problem
- Molecular Endotypes of Chronic Idiopathic UrticariaActive, not recruitingNCT04774315Phase 4How we knowReport a problem
- COVID-19 Immunologic Antiviral Therapy With OmalizumabStatus unknownNCT04720612Phase 2How we knowReport a problem
- Study of Pharmacokinetics, Pharmacodynamics and Safety Assessment of GNR-044 (JSC GENERIUM, Russia) and Xolair®CompletedNCT04601389Phase 1How we knowReport a problem
- Preclinical Studies of Omalizumab in Chronic Rhinosinusitis With Nasal PolyposisCompletedNCT04583501Early Phase 1How we knowReport a problem
- Xolair Interventional Study in ASD Patients With Comorbid AtopyWithdrawnNCT04535817Phase 1How we knowReport a problem
- The Efficacy of Preseasonal Omalizumab TreatmentCompletedNCT04489121Not applicableHow we knowReport a problem
- Behandling af Boern Med Foedevareallergi Med Omalizumab (Xolair)CompletedNCT04037176Phase 4How we knowReport a problem
- Protection From Food Induced Anaphylaxis by Reducing the Serum Level of Specific IgE (Protana).TerminatedNCT03964051Phase 4How we knowReport a problem
- Treatment With the Anti-IgE Monoclonal Antibody Omalizumab in Women With Asthma Undergoing Fertility Treatment. - A Proof of Concept Study.CompletedNCT03727971Phase 2How we knowReport a problem
- Omalizumab Treatment in Venom Immunotherapy With Systemic ReactionsStatus unknownNCT02968394Not applicableHow we knowReport a problem
- Three-month, Single-center Study to Identify Biomarkers/Response to Xolair Therapy in Chronic Idiopathic UrticariaCompletedNCT02814630Not applicableHow we knowReport a problem
- Preventing Asthma in High Risk KidsActive, not recruitingNCT02570984Phase 2How we knowReport a problem
- Treatment of Severe Peanut Allergy With Xolair (Omalizumab) and Oral ImmunotherapyStatus unknownNCT02402231Phase 2How we knowReport a problem
- Role of Anti-IgE in Severe Childhood EczemaCompletedNCT02300701Phase 4How we knowReport a problem
- Role of Omalizumab in Reducing the Incidence of Oxaliplatin-induced Hypersensitivity ReactionCompletedNCT02266355Phase 1How we knowReport a problem
- Efficacy and Safety of Omalizumab in Patients With Severe Acute UrticariaStatus unknownNCT02191072Not applicableHow we knowReport a problem
- Efficacy and Safety of Omalizumab in Chronic Idiopathic UrticariaStatus unknownNCT02166151Phase 3How we knowReport a problem
- Study of Omalizumab as Adjuvant Therapy in Chemotherapy DesensitizationCompletedNCT02118987Phase 1How we knowReport a problem
- Study of the Steroid Sparing Effect of Xolair (Omalizumab) in Patients With Persistent Eosinophilic BronchitisCompletedNCT02049294Phase 2/3How we knowReport a problem
- Efficacy Study of Omalizumab in Cholinergic UrticariaCompletedNCT02012387Phase 2How we knowReport a problem
- Safety and Efficacy Study of Omalizumab to Treat Allergic AsthmaCompletedNCT01976208Phase 2/3How we knowReport a problem
- Prospective Double-blind Placebo-controlled Study of the Effect of Xolair (Omalizumab) in Chronic Urticaria PatientsCompletedNCT01803763Phase 2/3How we knowReport a problem
- Omalizumab for LupusCompletedNCT01716312Phase 1How we knowReport a problem
- Efficacy and Safety Study of Omalizumab (Xolair®) to Treat Chronic UrticariaCompletedNCT01713725Phase 2How we knowReport a problem
- Single Center Study Using Omalizumab in Subjects With Atopic DermatitisCompletedNCT01678092Phase 1How we knowReport a problem
- mRNA Expression as a Biomarker of Omalizumab ResponseStatus unknownNCT01584687Phase 4How we knowReport a problem
- Clinical and Biological Effects of Anti-IgE (Omalizumab) in Patients With Bilateral Nasal Polyposis and AsthmaCompletedNCT01393340Phase 2How we knowReport a problem
- Long-term Safety, Tolerability and Efficacy of Omalizumab in Japanese ChildrenCompletedNCT01328886Phase 3How we knowReport a problem
- Omalizumab in Interstitial Cystitis/Bladder Pain SyndromeCompletedNCT01294878Phase 3How we knowReport a problem
- Atopic Dermatitis Biomarker Identification Trial in Omalizumab UsageCompletedNCT01179529Phase 2How we knowReport a problem
- Pharmacokinetics and Pharmacodynamics, Efficacy and Safety of Omalizumab in Japanese Children (6 - 15 Years)CompletedNCT01155700Phase 3How we knowReport a problem
- Omalizumab in Non-atopic AsthmaStatus unknownNCT01113437Phase 2/3How we knowReport a problem
- Identifying Responders to Xolair (Omalizumab) Using Eosinophilic Esophagitis as a Disease ModelCompletedNCT01040598Phase 1How we knowReport a problem
- Xolair Treatment for Milk Allergic ChildrenCompletedNCT00968110Early Phase 1How we knowReport a problem
- Exploratory Study of Xolair in Chronic Obstructive Pulmonary Disease in Patients With Elevated IgE LevelsWithdrawnNCT00851370Phase 2How we knowReport a problem